Skip to main content
Top
Published in: International Journal of Clinical Oncology 4/2020

01-04-2020 | Metastasis | Original Article

LINC00163 inhibits the invasion and metastasis of gastric cancer cells as a ceRNA by sponging miR-183 to regulate the expression of AKAP12

Authors: Jun Zhang, Hai-yan Piao, Shuai Guo, Yue Wang, Tao Zhang, Zhi-chao Zheng, Yan Zhao

Published in: International Journal of Clinical Oncology | Issue 4/2020

Login to get access

Abstract

Background

Gastric cancer (GC) is the most common and aggressive cancer of the digestive system and poses a serious threat to human health. Since genes do not work alone, our aim was to elucidate the potential network of mRNAs and noncoding RNAs (ncRNAs) in this study.

Methods

Transcriptome data of GC were obtained from TCGA. R and Perl were used to obtain the differentially expressed RNAs and construct a competing endogenous RNA (ceRNA) regulatory network. To investigate the biological functions of differentially expressed RNAs, loss-of-function and gain-of-function experiments were performed. Real-time PCR (RT-qPCR), western blot analysis, dual-luciferase reporter assays and fluorescence in situ hybridization were conducted to explore the underlying mechanisms of competitive endogenous RNAs (ceRNAs).

Results

Based on TCGA data and bioinformatics analysis, we identified the LINC00163/miR-183/A-Kinase Anchoring Protein 12 (AKAP12) axis. We observed that AKAP12 was weakly expressed in GC and suppressed invasion and metastasis in GC cells, which could be abolished by miR-183. In addition, LINC00163 can be used as a ceRNA to inhibit the expression of miR-183, thus enhancing the anticancer effect of AKAP12.

Conclusion

Our results demonstrated that weak LINC00163 expression in GC can sponge miR-183 to promote AKAP12. We established that the LINC00163/miR-183/AKAP12 axis plays an important role in GC invasion and metastasis and may be a potential biomarker and target for GC treatment.
Appendix
Available only for authorised users
Literature
2.
go back to reference Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (London, England) 393(10184):1948–1957. https://doi.org/10.1016/s0140-6736(18)32557-1 CrossRef Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (London, England) 393(10184):1948–1957. https://​doi.​org/​10.​1016/​s0140-6736(18)32557-1 CrossRef
12.
go back to reference Li C, Deng L, Zhi Q et al (2016) MicroRNA-183 functions as an oncogene by regulating PDCD4 in gastric cancer. Anticancer Agents Med Chem 16(4):447–455CrossRefPubMed Li C, Deng L, Zhi Q et al (2016) MicroRNA-183 functions as an oncogene by regulating PDCD4 in gastric cancer. Anticancer Agents Med Chem 16(4):447–455CrossRefPubMed
21.
go back to reference Xia W, Unger P, Miller L et al (2001) The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 61(14):5644–5651PubMed Xia W, Unger P, Miller L et al (2001) The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 61(14):5644–5651PubMed
29.
go back to reference Jin Z, Hamilton JP, Yang J et al (2008) Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Prev Biomark 17(1):111CrossRef Jin Z, Hamilton JP, Yang J et al (2008) Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Prev Biomark 17(1):111CrossRef
33.
go back to reference Guo X, Wei Y, Wang Z et al (2018) LncRNA LINC00163 upregulation suppresses lung cancer development though transcriptionally increasing TCF21 expression. Am J Cancer Res 8(12):2494–2506PubMedPubMedCentral Guo X, Wei Y, Wang Z et al (2018) LncRNA LINC00163 upregulation suppresses lung cancer development though transcriptionally increasing TCF21 expression. Am J Cancer Res 8(12):2494–2506PubMedPubMedCentral
Metadata
Title
LINC00163 inhibits the invasion and metastasis of gastric cancer cells as a ceRNA by sponging miR-183 to regulate the expression of AKAP12
Authors
Jun Zhang
Hai-yan Piao
Shuai Guo
Yue Wang
Tao Zhang
Zhi-chao Zheng
Yan Zhao
Publication date
01-04-2020
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 4/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01604-w

Other articles of this Issue 4/2020

International Journal of Clinical Oncology 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine